- Home
- HIO vs IMMP Comparison
HIO vs IMMP Comparison
Compare HIO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIO
- IMMP
- Stock Information
- Founded
- HIO 1993
- IMMP 1987
- Country
- HIO United States
- IMMP Australia
- Employees
- HIO N/A
- IMMP N/A
- Industry
- HIO Finance/Investors Services
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- HIO Finance
- IMMP Health Care
- Exchange
- HIO Nasdaq
- IMMP Nasdaq
- Market Cap
- HIO 379.0M
- IMMP 304.0M
- IPO Year
- HIO N/A
- IMMP N/A
- Fundamental
- Price
- HIO $4.13
- IMMP $1.76
- Analyst Decision
- HIO
- IMMP Buy
- Analyst Count
- HIO 0
- IMMP 2
- Target Price
- HIO N/A
- IMMP $8.50
- AVG Volume (30 Days)
- HIO 305.3K
- IMMP 77.9K
- Earning Date
- HIO 01-01-0001
- IMMP 03-18-2025
- Dividend Yield
- HIO 10.33%
- IMMP N/A
- EPS Growth
- HIO N/A
- IMMP N/A
- EPS
- HIO N/A
- IMMP N/A
- Revenue
- HIO N/A
- IMMP $3,019,249.00
- Revenue This Year
- HIO N/A
- IMMP N/A
- Revenue Next Year
- HIO N/A
- IMMP $47.79
- P/E Ratio
- HIO N/A
- IMMP N/A
- Revenue Growth
- HIO N/A
- IMMP 24.11
- 52 Week Low
- HIO $3.52
- IMMP $1.66
- 52 Week High
- HIO $4.03
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- HIO 70.93
- IMMP 35.48
- Support Level
- HIO $4.03
- IMMP $1.84
- Resistance Level
- HIO $4.11
- IMMP $1.94
- Average True Range (ATR)
- HIO 0.04
- IMMP 0.10
- MACD
- HIO 0.01
- IMMP -0.02
- Stochastic Oscillator
- HIO 86.11
- IMMP 3.03
About HIO Western Asset High Income Opportunity Fund Inc.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests in various sectors such as auto components, hotels, restaurants and leisure, household durables, food & staples, energy, banks, capital markets, consumer finance, insurance, pharmaceuticals, aerospace and defense, and others.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.